1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Verici Dx plc

Verici Dx plc

VRCDF
Verici Dx plcUS flagOther OTC
0.00
USD
- -
- -
6.86MMarket Cap
Verici Dx plc
VRCDF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
FRC
- -
- -
- -
0.01
0.01
- -
Revenue per Share
- -
-0.06
-0.07
-0.05
-0.03
-0.01
Basic EPS, GAAP
- -
-0.05
-0.07
-0.04
-0.03
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
0.14
0.08
0.07
0.02
0.02
- -
Book Value per Share
0.13
0.07
0.06
0.01
0.01
- -
Tangible Book Value per Share
- -
142
165
170
233
798
Basic Weighted Avg Shares
- -
- -
- -
1
3
4
Sales/Revenue/Turnover
- -
- -
- -
-875.32
-182.87
-190.28
Operating Margin (%)
- -
- -
1
1
1
1
Depreciation Expense
- -
-8
-11
-9
-6
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-862.19
-175.92
-189.22
Profit Margin (%)
17
9
8
- -
3
4
Working Capital
- -
- -
1
- -
- -
- -
LT Debt
20
12
12
4
5
7
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-52.7
-97.11
-115.94
-133.15
-117.81
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-8.09%
23.55%
Free Cash Flow
- -
- -
36.07%
Net Income, GAAP
- -
- -
18.03%
Sales/Revenue/Turnover
- -
- -
9.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
4

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.05
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Illumina, Inc. (ILU.DE)
Monash IVF Group Limited (MVF.AX)
BillionToOne, Inc. (BLLN)
Prostatype Genomics AB (publ) (PROGEN.ST)
Revvity, Inc. (RVTY)
Sonic Healthcare Limited (SKHCF)
Business
Verici Dx plc operates as an immuno-diagnostics innovator, concentrating its efforts within the kidney transplantation field. The company is actively developing advanced prognostic and diagnostic solutions for individuals undergoing kidney transplants. Its product pipeline includes Clarava, a pre-transplant test designed to predict the likelihood of early acute rejection; Tuteva, a post-transplant diagnostic focusing on acute cellular rejection, including sub-clinical forms; and Protega, a liquid biopsy aimed at foreseeing the risk of fibrosis and eventual graft failure. Leveraging AI-enhanced RNA signature analysis, Verici Dx strives to deliver personalized, data-driven insights to clinicians. Established in 2020, the firm maintains its base in Penarth, United Kingdom.

Company News

Company News APIChatGPT

  • proactiveinvestors.co.uk

    Verici Dx gains Olink Certified Service Provider status to expand proteomics offering

  • businesswire.com

    Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test

  • businesswire.com

    Verici Dx Collaborators to Present Data on Predictive Value of Tutivia™ for Acute Kidney Transplant Rejection at ATC 2026

  • businesswire.com

    CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients

  • businesswire.com

    Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients

  • proactiveinvestors.co.uk

    Verici Dx rises after passing key US laboratory accreditation audit

  • proactiveinvestors.co.uk

    Verici Dx climbs on 'preferred provider' deal with US healthcare network

  • seekingalpha.com

    Verici Dx plc - Special Call

  • proactiveinvestors.co.uk

    Verici Dx shares jump 23% as transplant test rollout gathers pace

  • proactiveinvestors.co.uk

    Verici Dx plans fresh funding round to boost US test rollout

  • proactiveinvestors.co.uk

    Verici Dx soars as Tutivia tests are confirmed by Medicare

  • proactiveinvestors.co.uk

    Verici Dx says its seen a significant increase in Tutivia orders

  • businesswire.com

    FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians